|
시장보고서
상품코드
2056331
유전자 발현 분석 시장 보고서 : 제품 및 서비스별, 기술별, 생산능력별, 최종 사용자별, 지역별(2026-2034년)Gene Expression Analysis Market Report by Products & Services, Technology (Polymerase Chain Reaction, Next Generation Sequencing, DNA Microarray, Sanger Sequencing, and Others), Capacity, End-User, and Region 2026-2034 |
||||||
세계의 유전자 발현 분석 시장 규모는 2025년에 60억 달러에 이르렀습니다. 향후는 2026-2034년에 CAGR 7.88%로 성장하여 2034년까지 121억 달러에 이를 것으로 예측했습니다.
유전자 발현 분석(GEA)이란, 생물학적 시스템의 거동을 조사하기 위해 유전자에서 데이터를 추출하는 기법입니다. 여기에는 유전자의 전사, 번역, 단백질의 번역 후 변형, RNA 스플라이싱 등 다양한 과정이 포함됩니다. 이 분석을 통해 얻은 데이터는 단백질, 리보핵산(RNA) 및 다양한 미생물학적 제품의 생산에 활용됩니다. 또한, 신약 개발이나 기존 진단법의 개선에도 활용되고 있습니다. GEA는 현재 수많은 질환을 유발하는 기전을 규명하는 데 필수적이라는 점이 널리 인정받고 있으며, 이에 따라 약물유전체학, 바이오마커, 독성학, 진단학 분야에서 폭넓게 활용되고 있습니다.
표적 분자 치료법의 도입 확대와 맞춤형 의료에 대한 수요 증가는 시장 성장을 견인하는 주요 요인 중 하나입니다. GEA는 유전자 기능을 규명하고, 질환을 진단하며, 신약 개발을 촉진하는 데 활용되는 분자생물학 연구 분야에서 강력한 도구임이 입증되었습니다. 또한 암, 결핵, 심혈관 질환, 유전성 질환 등 만성 질환의 유병률 증가가 시장 성장에 큰 견인 역할을 하고 있습니다. 또한, 이러한 질환을 치료하기 위한 맞춤형 의료의 개발로 인해 개별 환자의 필요에 맞춘 진단법 및 치료법의 변경이 가능해졌습니다. 또한, 차세대 염기서열 분석(NGS)의 등장과 유전체 데이터베이스 구축과 같은 다양한 기술적 진보에 더해, GEA의 성공률 향상 및 유전자 치료 분야의 연구 개발(R&D)에 대한 집중도가 높아짐에 따라 시장 성장이 더욱 가속화될 것으로 전망됩니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 유전자 발현 분석 시장
제6장 시장 분석 : 제품 및 서비스별
제7장 시장 분석 : 기술별
제8장 시장 분석 : 용량별
제9장 시장 분석 : 최종 사용자별
제10장 시장 분석 : 지역별
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 지표
제15장 경쟁 구도
JHS 26.06.15The global gene expression analysis market size reached USD 6.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 12.1 Billion by 2034, exhibiting a growth rate (CAGR) of 7.88% during 2026-2034.
Gene expression analysis (GEA) is the method of extracting data from a gene to investigate the behaviour of biological systems. It involves different processes such as gene transcription, translation, post-translational modification of protein and RNA splicing. The data obtained from this analysis is used for the production of proteins, Ribonucleic Acid (RNA) and various microbiological products. They are further utilized for the development of new drugs and improving the existing diagnostic methods. GEA is now widely considered to be essential in explaining the mechanisms that cause numerous medical ailments, owing to which it finds extensive applications in pharmacogenomics, biomarking, toxicology and diagnostics.
The increasing adoption of targeted molecular therapeutics, along with the growing demand for personalized medicines, is among the key factors driving the growth of the market. GEA has proven to be a powerful tool in molecular biology studies, which are used to understand the functioning of genes, diagnose ailments and facilitate drug development. Furthermore, the growing prevalence of chronic diseases, such as cancer, tuberculosis, and cardiovascular and genetic disorders is providing a significant boost to the market growth. Additionally, the development of personalized medicines to cure these ailments has enabled the modifications of diagnostic and treatment methods according to the individual patient requirement. Moreover, various technological advancements, such as the advent of Next Generation Sequencing (NGS), along with the development of genomic databases, higher success rates of GEA and enhanced focus on research and development (R&D) in gene therapy, are further projected to drive the market growth.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global gene expression analysis market report, along with forecasts at the global, regional and country levels from 2026-2034. Our report has categorized the market based on products & services, technology, capacity and end-user.
Breakup by Products & Services:
- Consumables
- Instruments
- Services
Breakup by Technology:
- Polymerase Chain Reaction (PCR)
- Next Generation Sequencing (NGS)
- DNA Microarray
- Sanger Sequencing
- Others
Breakup by Capacity:
- Low-to Mid-Plex Gene Expression Analysis
- High-Plex Gene Expression Analysis
Breakup by End-User:
- Pharmaceutical and Biotech Companies
- Academic Institutes and Research Centers
- Others
Breakup by Region:
- North America
- United States
- Canada
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Chile
- Peru
- Others
- Middle East and Africa
- Turkey
- Saudi Arabia
- Iran
- United Arab Emirates
- Others
Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Agilent Technologies, Inc., BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Eurofins GSC Lux SARL, F. Hoffmann-La Roche Ltd, GE Healthcare, Illumina, Inc., Oxford Gene Technology IP Limited, Pacific Biosciences of California Inc., PerkinElmer Inc., QIAGEN GmbH, Thermo Fisher Scientific Inc. etc.
Key Questions Answered in This Report
1. How big is the global gene expression analysis market?
2. What is the expected growth rate of the global gene expression analysis market during 2026-2034?
3. What are the key factors driving the global gene expression analysis market?
4. What has been the impact of COVID-19 on the global gene expression analysis market?
5. What is the breakup of the global gene expression analysis market based on the product & services?
6. What is the breakup of the global gene expression analysis market based on the technology?
7. What is the breakup of the global gene expression analysis market based on the capacity?
8. What is the breakup of the global gene expression analysis market based on the end-user?
9. What are the key regions in the global gene expression analysis market?
10. Who are the key players/companies in the global gene expression analysis market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Gene Expression Analysis Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact Of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Products & Services
- 6.1 Consumables
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Instruments
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Services
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Technology
- 7.1 Polymerase Chain Reaction (PCR)
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Next Generation Sequencing (NGS)
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 DNA Microarray
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Sanger Sequencing
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by Capacity
- 8.1 Low-to Mid-Plex Gene Expression Analysis
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 High-Plex Gene Expression Analysis
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by End-User
- 9.1 Pharmaceutical and Biotech Companies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Academic Institutes and Research Centers
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Europe
- 10.2.1 Germany
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 France
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 United Kingdom
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 Italy
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Spain
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Russia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 Germany
- 10.3 Asia-Pacific
- 10.3.1 China
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 Japan
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 India
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 South Korea
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Australia
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Indonesia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 China
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Argentina
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.4 Colombia
- 10.4.4.1 Market Trends
- 10.4.4.2 Market Forecast
- 10.4.5 Chile
- 10.4.5.1 Market Trends
- 10.4.5.2 Market Forecast
- 10.4.6 Peru
- 10.4.6.1 Market Trends
- 10.4.6.2 Market Forecast
- 10.4.7 Others
- 10.4.7.1 Market Trends
- 10.4.7.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Turkey
- 10.5.1.1 Market Trends
- 10.5.1.2 Market Forecast
- 10.5.2 Saudi Arabia
- 10.5.2.1 Market Trends
- 10.5.2.2 Market Forecast
- 10.5.3 Iran
- 10.5.3.1 Market Trends
- 10.5.3.2 Market Forecast
- 10.5.4 United Arab Emirates
- 10.5.4.1 Market Trends
- 10.5.4.2 Market Forecast
- 10.5.5 Others
- 10.5.5.1 Market Trends
- 10.5.5.2 Market Forecast
- 10.5.1 Turkey
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
- 12.1 Overview
- 12.2 Inbound Logistics
- 12.3 Operations
- 12.4 Outbound Logistics
- 12.5 Marketing and Sales
- 12.6 Service
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Indicators
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Agilent Technologies, Inc.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 BGI Genomics Co., Ltd.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.3 Bio-Rad Laboratories, Inc.
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Eurofins GSC Lux SARL
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.5 F. Hoffmann-La Roche Ltd
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.6 GE Healthcare
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.7 Illumina, Inc.
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Oxford Gene Technology IP Limited
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.9 Pacific Biosciences of California Inc.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.10 PerkinElmer Inc.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 QIAGEN GmbH
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.12 Thermo Fisher Scientific Inc.
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.12.4 SWOT Analysis
- 15.3.1 Agilent Technologies, Inc.
